The FDA has approved a linagliptin/metformin hydrochloride combination tablet (Jentadueto, Boehringer Ingelheim and Eli Lilly) for use in people with type 2 diabetes. Taken twice-daily, the drug is indicated for use along with diet and exercise to improve glycemic control.
Source: Boehringer Ingelheim.
